The Permanente Medical Group, Inc. - N.CaliforniaOB/GYN: Reproductive Endocrinologist in Santa Clara The Permanente Medical Group, Inc. - N.CaliforniaOB/GYN: Reproductive Endocrinologist in Santa ClaraCampbell, CA$582,000–$600,000 / yearThe Kaiser Permanente Northern California region has three well-established and successful IVF centers located in Fremont, Sacramento, and San Francisco, which operate as a group practice and collectively manage 3,000 cycles annually. The Permanente Medical Group, Inc., (TPMG) is one of the largest medical groups in the nation with over 10,000 physicians, 21 medical centers, numerous clinics throughout Northern and Central California and an 80-year tradition of providing quality medical care.
Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare DiseaseSan Jose, CARemote$130,000–$170,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Taylor Strategy PartnersNewSpecialty Sales Representative - Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative - Cardiometabolic Rare DiseaseSan Jose, CARemote$130,000–$170,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.